Lutathera<sup>®</sup>: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy.

Pharmaceuticals (Basel) · 2019 · PMC6789871 · PMID 31362406

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp < 0.0001actually significant

There was a highly significant difference ( p < 0.0001) between the two groups: At 20 months, 65% of patients in the [ 177 Lu]Lu-DOTA-TATE group were living and free of progression, compared to only 11% in the control group [ 8 , 13 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.